The ASC Intelligence Gap

Executive Summary

Ambulatory surgical centers (ASCs) are entering a period of structural opportunity—and structural exposure. Medicare is expanding the procedures that may be paid in outpatient settings, narrowing selected hospital site-of-service advantages, and proposing payment changes that vary sharply by code. At the same time, Congress is advancing price-transparency legislation that would reach ASCs for the first time, Medicare Advantage (MA) now covers the majority of Medicare beneficiaries and increasingly adjudicates site of service directly, and CMS is tightening program-integrity oversight.

These developments are often described separately: site neutrality, the inpatient-only list, ASC payment updates, direct contracting, cash-pay bundles, transparency mandates, prior authorization, and enrollment enforcement. Taken together, they reveal a more consequential transition. The ASC market is moving from an era in which eligibility and contracted reimbursement largely determined opportunity to one in which organizations must continuously determine whether each episode is clinically appropriate, financially viable, competitively priced, and regulatorily defensible.

The Operating Paradox

More procedures may become eligible for ASCs while the margin, complexity, and compliance risk of those procedures become harder to manage.

The scale of the sector makes the stakes concrete. MedPAC reported 6,436 Medicare-certified ASCs in 2024, a 2.2% increase over the prior year.¹ In that year, 3.4 million fee-for-service Medicare beneficiaries received 6.4 million ASC procedures, generating $7.5 billion in Medicare program payments and beneficiary cost sharing.² Medicare spending per fee-for-service beneficiary on ASC services increased 15.9% from 2023 to 2024—while ASC volume per 1,000 beneficiaries grew only 3.4%.

Read those two numbers together and the argument of this paper is already visible. In 2024, Medicare ASC payment growth substantially outpaced procedure-volume growth. Rate changes and service mix—not case count alone—drove the increase.

Revenue also remains extraordinarily concentrated: twelve procedures accounted for half of fee-for-service Medicare surgical-procedure revenue in ASCs in 2024, seven procedures accounted for half of volume, and cataract extraction with intraocular lens insertion alone accounted for roughly 18% of fee-for-service ASC volume.

That concentration makes the headline "average update" a poor operating guide. A center experiences policy through its own case mix, code mix, payer mix, implant costs, staffing model, complication risk, and local market. Volume can grow while contribution margin deteriorates.

This paper introduces the ASC Intelligence Gap: the distance between the information an ASC possesses and the connected intelligence required to answer six questions before accepting an episode:

1. Is the procedure eligible in the proposed setting?
2. Is this patient clinically appropriate for that setting?
3. What will the payer—or direct purchaser—actually pay?
4. What will the complete episode cost, including variation and outlier exposure?
5. Can the organization demonstrate a competitive outcome?
6. Can the decision and the organization's participation withstand regulatory scrutiny?

Organizations that can answer these questions reliably will convert outpatient migration into durable advantage. Those that equate eligibility with profitability risk inheriting more volume, more complexity, and more accountability without sufficient margin or infrastructure.

Policy Status at a Glance

1. The End of Site-Based Certainty

For decades, ambulatory surgical centers operated in an environment of relative clarity. A procedure was either on the Medicare ASC-payable list or it was not. If a procedure was eligible, and the ASC had a contract with the payer, the business model was straightforward: schedule the case, manage implant and labor costs, and collect the facility fee. This site-based certainty was the foundation of the ASC boom.

However, in 2026, this certainty has dissolved. We have entered an era of site-of-care expansion that is structurally different from site neutrality. While CMS continues to expand the list of payable procedures in outpatient and ASC settings, Medicare Advantage plans—which now cover over 50% of Medicare beneficiaries—increasingly adjudicate site of service directly, using proprietary algorithms and restrictive clinical criteria.⁶ Prior authorizations have surged, and denials are frequently issued on the basis of patient selection, even when a procedure is technically eligible on a code level.⁷

This transition is accelerated by regulatory shifts. While CMS proposes payment changes that vary sharply by code, Congress is advancing price-transparency legislation that targets ASCs for the first time. The days of relying on a standard "average update" or assuming that any eligible case will yield a positive margin are over. An ASC's success now depends on its ability to connect policy, patient selection, pricing, margin, and compliance into a single operational framework.

2. What Eligibility Does Not Guarantee

A common misconception among outpatient strategists is that regulatory eligibility translates directly into clinical volume and financial profitability. History proves otherwise.

Consider Total Knee Arthroplasty (TKA), which was removed from the Inpatient Only (IPO) list and made payable in ASCs in 2020. Despite five years of eligibility, TKA and other complex orthopedic procedures represent an incredibly small fraction of total ASC volume. In 2024, Medicare fee-for-service paid for just 49,258 ASC TKAs and 11,047 Total Shoulder Arthroplasties (TSA)—against 6.4 million total ASC procedures.² Combined, these highly publicized procedures represented less than 1% of total ASC procedure volume.

Why is there such a massive gap between eligibility and volume? The answer lies in several structural barriers:

1. The Rate Gap: The payment disparity between settings is structural, not incidental. MedPAC reports that "for most services, the ASC payment rates are 46 percent lower than the HOPD payment rates."¹ For instance, in 2026, the ASC conversion factor was $56.32, compared to an OPPS conversion factor of $90.97.³ This rate gap means that ASCs must operate with extreme efficiency to cover the high cost of implants and specialized labor.
2. Clinical Eligibility vs. Administrative Eligibility: While a code is administratively payable, many patients are clinically inappropriate for an ASC due to comorbidities, anesthesia risks, or lack of post-discharge support.
3. Payer Adjudication: Medicare Advantage plans and commercial insurers utilize prior authorization to restrict outpatient migration, often denying cases that do not meet their narrow clinical criteria.
4. Information Asymmetry: ASCs rarely submit standardized cost reports to Medicare, leaving them without robust benchmarks to evaluate their true cost of care. As MedPAC notes, "ASCs do not submit cost reports, so we cannot analyze the financial standing for all ASCs."¹ This lack of financial visibility makes it difficult to assess whether high-acuity cases are truly profitable.

3. The Six Questions Every ASC Must Answer Before Accepting an Episode

To close the intelligence gap, ASC leaders must move away from retrospective financial reviews and implement a prospective, connected decision framework. Before scheduling any high-acuity outpatient episode, the organization must be able to answer six fundamental questions:

1. Is the procedure eligible in the proposed setting?

Every analysis must begin with code-level eligibility. ASCs must continuously track the CMS ASC-payable list, local coverage determinations (LCDs), and payer-specific policy updates. A code that is eligible under fee-for-service Medicare may be restricted or subject to different billing guidelines under a commercial or Medicare Advantage contract.

2. Is this patient clinically appropriate for that setting?

Clinical safety must always precede financial analysis. ASCs must establish standardized, objective screening protocols that evaluate patient-specific factors such as BMI, cardiac history, sleep apnea, ASA physical status classification, and social support. Accepting a high-risk patient who ultimately requires an unplanned hospital transfer destroys both the center's clinical reputation and its financial margin.

3. What will the payer—or direct purchaser—actually pay?

Contracted rates vary widely, particularly in the commercial and Medicare Advantage markets. ASCs must have real-time visibility into the exact allowed amount for each payer-contract combination, including any carve-outs for implants or supply costs. Relying on average historical collections is no longer sufficient when managing low-margin, high-implant-cost procedures.

4. What will the complete episode cost, including variation and outlier exposure?

ASCs must transition from "per-case" costing to "episode-of-care" costing. This requires mapping all labor, supply, implant, and overhead costs, as well as accounting for potential clinical variation (e.g., extended recovery times, additional supplies, or post-operative complications). If the cost of the implant alone consumes 70% of the facility fee, the case may not be financially viable without a specialized payer contract.

5. Can the organization demonstrate a competitive outcome?

In an era of price transparency and direct contracting, purchasers are demanding outcomes data. ASCs must actively participate in clinical registries and track patient-reported outcome measures (PROMs). Being able to prove lower infection rates, faster recovery times, and higher patient satisfaction is essential for securing favorable contracts with commercial payers and self-insured employers.

6. Can the decision and the organization's participation withstand regulatory scrutiny?

Compliance is the ultimate safeguard of an ASC's margin. Federal regulators are expanding their oversight of outpatient medical necessity, coding accuracy, and financial relationships. Every clinical and operational decision must be backed by contemporaneous, defensible documentation that can withstand post-payment audits and program-integrity reviews.

4. The Enrollment Sleeper Risk

While prior authorization and medical necessity denials represent immediate threats to ASC revenue, a quieter but equally devastating risk is emerging around provider enrollment and program integrity.

CMS is actively strengthening its oversight of Medicare enrollment under proposed rule CMS-1844-P.⁸ This initiative is designed to weed out billing anomalies, unapproved practice locations, and outdated provider associations. For ASCs, this represents a significant operational vulnerability.

Many ASCs operate complex joint-venture models with multiple physician owners and rotating staff. If a billing provider's enrollment record contains even a minor discrepancy—such as an outdated suite number, an unvalidated billing address, or an inactive physician association—the consequences can be severe. Under the new enforcement framework, technical enrollment discrepancies can trigger immediate, automatic payment suspensions and retroactive recoupments. Payers are using these enrollment audits as a highly effective tool to pause cash flow and conduct retrospective reviews, turning a clerical error into an existential financial crisis.

5. The Three ASC Futures

How ASC organizations navigate the intelligence gap will define their trajectory over the next decade. The market is dividing into three distinct strategic postures:

6. Intelligence-Led Strategy

To thrive as an Intelligent Operator, ASC leaders must bridge the intelligence gap by investing in connected technology and clinical intelligence.

ClinEfficiency Pro builds the AI-powered healthcare intelligence tools required for this transition. Our platform, including PAULA, provides utilization management, payer policy monitoring, denial risk assessment, and physician advisor workflows tailored specifically for outpatient and ASC environments. By connecting clinical criteria with real-time financial and policy data, ClinEfficiency Pro enables organizations to transition from passive eligibility tracking to prospective, strategic episode management.

Closing the intelligence gap is not just an operational improvement—it is the defining strategic differentiator for the outpatient market.

7. References

1. MedPAC. Medicare Payment Advisory Commission Report to Congress: Medicare Payment Policy. March 2025. Available at medpac.gov. ↩
2. MedPAC. Medicare Payment Advisory Commission Report to Congress: Medicare Payment Policy. March 2024. ↩
3. CMS. CY 2026 OPPS/ASC Final Rule (CMS-1834-FC). November 2025. Available at federalregister.gov. ↩
4. CMS. CY 2027 OPPS/ASC Proposed Rule (CMS-1850-P). July 2026. Available at cms.gov. ↩
5. CMS. CY 2027 Physician Fee Schedule Proposed Rule. July 2026. ↩
6. U.S. Senate Permanent Subcommittee on Investigations. Denied, Delayed, Disconnected. June 2024. ↩
7. OIG. Some Medicare Advantage Organizations Delayed or Denied Beneficiary Access to Post-Acute Care. April 2022. ↩
8. CMS. Strengthening Oversight of Medicare Enrollment (CMS-1844-P). 2026. ↩